 |
| Anno I | Numero 8 | Dicembre 2016 |
| Comitato scientifico editoriale: Paolo A. Ascierto, Vanna Chiarion-Sileni Editore: Intermedia – Direttore Responsabile: Mauro Boldrini |
| Notizie dalla ricerca |
| Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial |
| The anti-PD-1 agent, nivolumab, has been approved both as monotherapy and in combination with ipilimumab for the treatment of unresectable or metastatic melanoma in the USA and European Union. Here we present the case of a patient with treatment-naive, metastatic mucosal melanoma and baseline LDH approximately seven times the upper limit of normal. The patient was enrolled in a clinical trial (CheckMate 066) and achieved a partial response, followed by a durable complete … |
| Continua a leggere |
| Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated with Pembrolizumab |
| Immune checkpoint blockade is associated with endocrine-related adverse events. Thyroid dysfunction during pembrolizumab therapy, an anti-programmed cell death 1 receptor (PD-1) monoclonal antibody (mAb), remains to be fully characterized. To assess the incidence and characteristics of pembrolizumab-associated thyroid dysfunction. Thyroid function was monitored prospectively in melanoma patients who initiated pembrolizumab within an expanded access program at … |
| Continua a leggere |
| Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events |
| In recent years, immune checkpoint inhibitors have emerged as effective therapies for advanced neoplasias. As new checkpoint target blockers become available and additional tumor locations tested, their use is expected to increase within a short time. Immune-related adverse events (irAEs) affecting the endocrine system are among the most frequent and complex toxicities. Some may be life-threatening if not recognized; hence, appropriate guidance for oncologists … |
| Continua a leggere |
| Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery |
| Growing evidence suggests that immunotherapy and radiation therapy can be synergistic in the treatment of cancer. This study was performed to determine the effect of the relative timing and type of immune checkpoint therapy on the response of melanoma brain metastases (BrMets) to treatment with stereotactic radiosurgery (SRS). Seventy-five melanoma patients with 566 BrMets were treated with both SRS and immune checkpoint therapy between 2007 and 2015 at a single institution. Immunotherapy … |
| Continua a leggere |
| Ipilimumab after progression on anti-PD-1 treatment in advanced melanoma |
| While both efficacy and safety of anti-PD-1 agents seem to be independent of previous treatment with anti-CTLA-4, limited data exist of efficacy and toxicity of ipilimumab after progression on anti-PD-1 therapy. This retrospective analysis describes the efficacy and safety of sequential therapy with ipilimumab in patients with metastatic melanoma who progressed on anti-PD-1 antibody. Nine patients who progressed on anti-PD-1 therapy received four cycles of ipilimumab 3 mg/kg … |
| Continua a leggere |
| Clinical Outcomes of Melanoma Brain Metastases Treated with Stereotactic Radiosurgery and Anti-PD-1 Therapy, Anti-CTLA-4 Therapy, BRAF/MEK Inhibitors, BRAF Inhibitor, or Conventional Chemotherapy |
| The effect of immunologic and targeted agents on intracranial response rates in patients with melanoma brain metastases (MBMs) is not yet clearly understood. This report analyzes outcomes of intact MBMs treated with single session SRS and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors(i), BRAFi, or conventional chemotherapy. Patients were included if MBMs were treated with single session SRS within 3 months of receiving systemic therapy. The primary endpoint … |
| Continua a leggere |
| Appuntamenti AIOM |
| Incontri di aggiornamento del dipartimento oncologico |
| Negrar (VR), 13 dicembre 2016 |
| Corso NIBIT di Formazione sulla Immunobioterapia dei Tumori Umani basi teoriche, risultati clinici e tossicità delle più promettenti strategie terapeutiche in oncologia |
| Candiolo (TO), 15 dicembre 2016 |
| Workshop Immuno-Oncologia IMI |
| Verona, 16 – 17 dicembre 2016 |
| Divulgare e utilizzare l’epidemiologia dei tumori |
| Padova, 19 dicembre 2016 |
| Questi e altri appuntamenti si possono consultare sul sito AIOM www.aiom.it |
| Editore: Intermedia s.r.l. – Via Malta 12/b, 25124 Brescia – tel. 030 226105 fax 030 2420472 – Reg. Trib. di Brescia n. 35/2001 del 2/7/2001 Per contattare la redazione e commentare le notizie clicca qui: redazione Per consultare i numeri arretrati della newsletter clicca qui: archivio Per sospendere la ricezione di questa newsletter clicca qui: AIOM news RIMUOVI |
Questo progetto è stato realizzato con il contributo di  |